SCHEMBL868472

SCHEMBL868472

C[C@]12CCC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 5/20 1.00
AKR1B10 O60218 2/20 1.00
AKR1B1 P15121 2/20 1.00
OR51E2 Q9H255 1/20 1.00
GPBAR1 Q8TDU6 5/20 0.65
SHBG P04278 4/20 0.65
CYP3A4 P08684 4/20 0.65
SERPINA6 P08185 3/20 0.65
NR3C1 P04150 1/20 0.65
PGR P06401 1/20 0.65
NR3C2 P08235 1/20 0.65
AR P10275 1/20 0.65
HSD17B10 Q99714 1/20 0.65
MGAM O43451 1/20 0.65
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
LMNA P02545 3/20 0.64
MAPK1 P28482 2/20 0.64
POLB P06746 1/20 0.64
HSD17B3 P37058 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL891363 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL1114187 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL15369324 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL12394882 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL868473 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL16305624 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL12377165 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL15426613 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL22844489 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL1331733 1.00 CYP19A1 (1.00) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260140124-A1 PCOS STRATIFICATION THE UNIVERSITY OF BIRMINGHAM (GB) 2026-05-21 US claimed
EP-4605743-A1 PCOS STRATIFICATION The University of Birmingham (GB) 2025-08-27 EP claimed
WO-2024084250-A1 PCOS STRATIFICATION THE UNIVERSITY OF BIRMINGHAM (GB) 2024-04-25 WO claimed
US-8623849-B2 Medicinal applications of benzoic acid hydrazones synthesized on the basis of steroidal tigogenin Shelar, Ashok Ranganath (IN) 2014-01-07 US claimed
EP-2279195-B1 MEDICINAL APPLICATIONS OF BENZOIC ACID HYDRAZONES SYNTHESIZED ON THE BASIS OF STEROIDAL TIGOGENIN SHELAR ASHOK RANGANATH (IN) 2013-05-15 EP claimed
EP-2279195-A1 MEDICINAL APPLICATIONS OF BENZOIC ACID HYDRAZONES SYNTHESIZED ON THE BASIS OF STEROIDAL TIGOGENIN Shelar, Ashok Ranganath (IN) 2011-02-02 EP claimed
US-20100317639-A1 Medicament Based On a Monoester of Steroids With Long Chain Fatty Acids PETRONI ANNA 2010-12-16 US claimed
EP-1962856-B1 MEDICAMENT BASED ON A MONOESTER OF STEROIDS WITH LONG CHAIN FATTY ACIDS PETRONI ANNA (IT) 2010-10-20 EP claimed
WO-2009144738-A1 MEDICINAL APPLICATIONS OF BENZOIC ACID HYDRAZONES SYNTHESIZED ON THE BASIS OF STEROIDAL TIGOGENIN SHELAR ASHOK RANGANATH (IN) 2009-12-03 WO claimed
EP-1807062-A4 USE OF ANDROGENS TO REDUCE THE LIKELIHOOD OF ACQUIRING OR TO TREAT SKIN AGING ENDORECH INC (CA) 2009-06-03 EP claimed
EP-1807062-A1 USE OF ANDROGENS TO REDUCE THE LIKELIHOOD OF ACQUIRING OR TO TREAT SKIN AGING Endorecherche Inc. (CA) 2007-07-18 EP claimed
US-20060178352-A1 Use of androgens to reduce the likelihood of acquiring or to treat skin aging ENDORECHERCHE, INC. 2006-08-10 US claimed
WO-2006047859-A1 USE OF ANDROGENS TO REDUCE THE LIKELIHOOD OF ACQUIRING OR TO TREAT SKIN AGING ENDORECHERCHE, INC. (CA) 2006-05-11 WO claimed
US-20020165195-A1 Method of treating androgen-dependent disorders SCHERING CORPORATION 2002-11-07 US claimed
EP-1102582-A2 INHIBITORS OF TYPE 3 3ALPHA-HYDROXYSTEROID DEHYDROGENASE Endorecherche Inc. (CA) 2001-05-30 EP claimed
WO-2000007576-A2 INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE ENDORECHERCHE, INC. (CA) 2000-02-17 WO claimed
US-20260140124-A1 PCOS STRATIFICATION THE UNIVERSITY OF BIRMINGHAM (GB) 2026-05-21 US disclosed
EP-4712980-A1 TREATMENT OF BREAST TISSUE Havah Therapeutics Pty Ltd (AU) 2026-03-25 EP disclosed
US-4102884-A TREATING A 3,14-DIHYDROXY-CARDENOLIDE WITH OXYGEN AND N-BROMOACETAMIDE IN THE PRESENCE OF PLATINUM, THEN WITH ETHANEDITHIOL, RANEY NICKEL STEELE CHEMICALS CO. LTD. (CA) 1978-07-25 US disclosed
US-4013688-A STEROIDS THE UPJOHN COMPANY (US) 1977-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317639-A1 Medicament Based On a Monoester of Steroids With Long Chain Fatty Acids ACAT1, ACAT2, HSD17B12 CYP19A1 99/4885AKR1B10 202/4885AKR1B1 152/4885
US-20260140124-A1 PCOS STRATIFICATION HSD17B3, AKR1C3, HSD17B11 CYP19A1 21/4885AKR1B10 20/4885AKR1B1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.